Karacin, CengizSunar, VeliUrakci, ZuhatYilmaz, AliAyhan, MuratErsoy, MustafaGuven, Deniz Can2024-04-242024-04-2420241479-66941744-8301https://doi.org/10.2217/fon-2023-0763https://hdl.handle.net/11468/18869Aim: To investigate the efficacy and safety of bevacizumab in patients with recurrent low-grade serous ovarian carcinoma. Materials & methods: The data of patients who received at least two cycles of bevacizumab in combination with chemotherapy were retrospectively recorded. Results: The median age of 51 patients was 56 (range: 33-75) years. The complete response rate was 10.4% and the partial response rate was 43.7%. The objective response rate was 54.1%. Median progression-free survival was 15.9 months (95% CI: 9.1-22.6) and median overall survival was 42.5 months (95% CI: 37.2-47.8). Conclusion: Bevacizumab with chemotherapy is an effective option for treating recurrent ovarian low-grade serous carcinoma.eninfo:eu-repo/semantics/closedAccessBevacizumabLow GradeOvarian CancerPeritoneumSerousTubaArticle204207214WOS:0011576710000012-s2.0-851858277493832889010.2217/fon-2023-0763Q2N/A